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Prospective trial of pulse oral versus intravenous calcitriol treatment of
hyperparathyroidism in ESRD. To examine the most effective route
(intravenous vs. "pulse" oral), dose (physiologic vs. pharmacologic)
and long-term efficacy of calcitriol therapy for secondary hyperparathy-
roidism in patients with end-stage renal disease (ESRD), we random-
ized 19 hemodialysis patients with severe hyperparathyroidism to
receive over a 36-week study period either pulse orally administered
calcitriol and intravenous placebo (pulse oral group; N 9) or intrave-
nous calcitriol and oral placebo (intravenous group; N = 10). Calcitriol
was given intermittently in a double-blinded fashion at an initial dose of
2 g thrice weekly and increased as tolerated up to a maximum dose of
4 g per treatment. All patients received similar daily calcium supple-
mentation (2.5 g of elemental calcium) and low dialysate calcium (1.25
mmol/liter) throughout the study period. At the maximum tolerated
calcitriol dose, serum 1 ,25-dihydroxyvitamin D levels were significantly
greater 60 minutes following intravenous (389 pmol/liter) compared to
oral administration (128 pmollliter). In spite of the different pharmaco-
logic profiles, intravenous and oral administered calcitriol resulted in
similar reductions of serum PTH over the 36 week period of observation(P = 0.300), achieving an overall maximum average PTH reduction of
43% (P = 0.016). Long-term intensive calcitriol therapy (independent of
administration route), however, failed to decrease parathyroid gland
size as assessed by high resolution ultrasound and/or magnetic reso-
nance imaging. Calcitriol therapy also failed to alter the calcium
sensitivity as assessed by serial PTH measurements in response to
calcium loading. Increases in serum calcium, but not calcitriol dose or
parathyroid gland size, predicted decrements in serum PTH, whereas
hyperphosphatemia and the level of PTH suppression derived from the
PTH/ionized calcium response curves predicted refractoriness to cal-
citriol therapy. Episodes of hypercalcemia and hyperphosphatemia
were similar in both treatment groups and limited the dose of calcitriol
that could be administered. These data indicate that intermittent
intensive calcitriol therapy, regardless of administration route, is poorly
tolerated, fails to correct parathyroid gland size and functional abnor-
malities, and has a limited ability to achieve sustained serum PTH
reductions in end-stage renal failure patients with severe hyperparathy-
roidism.
Secondary hyperparathyroidism of variable severity is found
in a large percentage of patients with end-stage renal failure [1].
Chronic elevations of serum PTH concentrations result both
from increases in the amount of PTH secretory tissue (glandular
hyperplasia) [2] as well as augmented cellular PTH biosynthesis
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and secretion [3—6]. Recent in vitro and in vivo studies indicate
that calcitriol deficiency also plays an important role in the
genesis of uremic secondary hyperparathyroidism [7—14]. Cal-
citriol deficiency, arising from diminished functional renal pa-
renchyma, is temporally correlated with the initial increase in
serum PTH levels in developing renal failure [7]. Moreover,
calcitriol suppresses parathyroid cell proliferation in cell culture
systems, prevents parathyroid gland hyperplasia in animal
models of secondary hyperparathyroidism [8, 9], and directly
reduces PTH gene transcription [4, 10—14] through interaction
with the vitamin D receptor. Correction of calcitriol deficiency,
therefore, may be important for the successful management of
secondary hyperparathyroidism in end-stage renal failure [4,
14—16].
Several unresolved issues remain, however, regarding use of
calcitriol in the treatment of secondary hyperparathyroidism.
Controversy exists regarding the optimum dose of calcitriol
(that is, physiologic vs. pharmacologic) and the most effective
method of its administration (that is, oral vs. intravenous).
Recent uncontrolled clinical investigations suggest that attain-
ing pharmacologic serum 1,25 dihydroxyvitamin D levels by
administering calcitriol intravenously is more effective in sup.
pressing serum PTH than orally administered calcitriol [17, 18].
In addition, these clinical trials propose that the intravenous
route of administration may be associated with fewer episodes
of hypercalcemia than orally administered calcitriol [17—20]. In
contrast, other uncontrolled studies indicate that daily or inter-
mittent oral administration of calcitriol can also suppress serum
PTH levels in hemodialysis patients with few complications,
provided that sufficient amounts of calcitriol are given to attain
physiologic serum 1,25 dihydroxyvitamin D concentrations (15,
16, 21—26). The latter conclusion is consistent with experimen-
tal data in animals showing that the majority of calcitriol-
mediated PTH gene suppression occurs in the physiologic
dosage range [12, 13]. The uncontrolled nature of the existing
clinical studies limit the conclusions that can be drawn regard-
ing the efficacy and tolerance of calcitriol administered by
different routes.
In addition, limited information is available regarding the
effect of calcitriol therapy on regression of parathyroid gland
hyperplasia and its long-term efficacy in patients with uremic
hyperparathyroidism. Studies in animal models indicate that
calcitriol administration will prevent the development of hyper-
plasia and suppress PTH biosynthesis but will not induce
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involution of pre-existing hyperplastic parathyroid tissue [9].
Indeed, therapeutic resistance to calcitriol observed in some
patients with ESRD may be related to persistent glandular
hyperplasia and/or intrinsic abnormalities of gland function
which are refractory to calcitriol actions [2, 20].
In an effort to resolve these issues, we performed a double
blind, randomized, placebo controlled trial comparing the ef-
fects of "pulse" oral with intravenous calcitriol therapy in
hemodialysis patients with secondary hyperparathyroidism. We
evaluated the effects of these two treatment strategies to
suppress serum intact PTH, reduce parathyroid gland size as
assessed by high resolution ultrasound and/or magnetic reso-
nance imaging, and normalize parathyroid gland function as
defined by dynamic suppression of PTH secretion in response
to calcium loading.
Methods
Patient selection
Twenty-three patients were recruited into the study from a
total population of 257 patients in four hemodialysis units.
Entry criteria included age between 18 and 65 years, thrice
weekly hemodialysis, and an intact serum PTH concentration
between 250 pg/mI and 2500 pg/mI. Patients were excluded from
consideration for the following reasons: prior treatment with
calcitriol or other vitamin D analogues in doses exceeding 0.5
sg/day, Type 1 diabetes, prior parathyroidectomy, unsuccess-
ful renal transplantation within one year, iron overload as
defined by a random serum ferritin exceeding 1000 nglml,
treatment in the prior six months with medications such as
phenobarbital, diphenylhydantoin, or glucocorticoid, which
may interfere with vitamin D and/or bone homeostasis, inade-
quate dialysis as evidenced by a pre-dialysis BUN greater than
120 mg/dl, total calcium exceeding 10.5 mg/dl and serum
phosphorus greater than 7.0 mg/dl, or serum aluminum greater
than 100 pjg/liter.
Study protocol
The study protocol consisted of an initial six-week control
period and a 36-week treatment period. The study protocol was
approved by the Internal Review Board at Duke University
Medical Center. All patients signed informed consent prior to
entering the study.
Control period. The control period was used to standardize
the dietary calcium and phosphorus intake and establish control
of serum phosphorus by administering phosphate binders ac-
cording to a standardized regimen. At the outset of the control
period all current calcium- and/or aluminum-containing phos-
phate binders and vitamin D preparations were discontinued. In
addition, all patients were switched to a dialysis solution
containing (1.25 mmol/liter) 2.5 mEq/liter calcium. In addition,
the patients were instructed to restrict their dietary elemental
phosphate intake to 900 mg per day and their elemental calcium
intake to 500 nig per day. Participants were asked to keep food
records on a periodic basis to help ensure compliance to the 900
mg phosphorus, 500 mg calcium diet prescription. On a bi-
monthly basis food records were tabulated or if food records
were not provided, a twenty-four hour dietary recall was
conducted by the dietician to calculate daily dietary calcium
and phosphorus intake. Nutrient analysis was done by the
Professional Diet Analyzer (CBORD; Ithica, New York, USA).
[27].
Efforts to control serum phosphate levels consisted of admin-
istering calcium carbonate (CaCO3) (OSCAL; Marion Merrell
Dow, Cincinnati, Ohio, USA) with meals up to a total daily
dose of 6.25 grams (2,5 gof elemental calcium). Higher doses of
calcium carbonate were administered only if the serum calcium
was below 2.1 mmol/liter (8.2 mg/dl) during the control period.
Aluminum carbonate (Basaljel, Wyeth Laboratories, Philadel-
phia, Pennsylvania, USA) was added to the regimen up to a
maximum dose of 4 grams per day if the serum phosphorus
exceeded 2.3 mmol/liter (7 mg/dl). Serum calcium and phospho-
rus concentrations were determined weekly throughout the
control period and doses of calcium carbonate and aluminum-
containing antacids adjusted (within the above stated limits) in
an attempt to maintain the serum phosphorus below 2.3 mmoll
liter (7 mg/dl) and the serum calcium above 2.1 mmol/liter (8.2
mg/dl).
Of the 23 patients who were initially enrolled, four subjects
failed to complete the six-week control period. Two subjects
requested to end involvement for unspecified personal reasons;
one patient was removed from the study because of uncon-
trolled hyperphosphatemia; and one patient was excluded due
to persistent hypophosphatemia secondary to poor nutrition.
Treatment period. Nineteen patients completed the control
period and were randomized to receive one of two possible
treatments: intravenous calcitriol/oral placebo (Intravenous
Group) or oral calcitriol/intravenous placebo (Pulse Oral
Group). The planned duration for the treatment period was 36
weeks. A restricted randomization technique was employed to
assign these study participants to the treatment groups. Sub-
jects were first placed according to their baseline (—6 weeks)
intact PTH concentration into classes with intervals of 200
pg/ml (that is, 200 to 399, 400 to 599, and so on). Individuals
within subgroups were paired and randomly allocated into the
two treatment groups using a table of random numbers. This
method preserved randomization to the degree possible while
assuring that the groups did not significantly differ with respect
to PTH prior to initiating therapies. Using this method, 10
patients were randomized to receive intravenous calcitriol and
oral placebo capsules, whereas nine patients received oral
calcitriol and intravenous placebo (Table 1).
Each dose of oral calcitriol or placebo was administered
thrice weekly at the end of each dialysis treatment as a single
dose. This method of oral calcitriol dosing has been referred to
as "pulse" oral administration [21—25]. Similarly, intravenous
calcitriol or a saline placebo injection was administered thrice
weekly at the end of each dialysis procedure. The physicians,
study coordinators and patients were blinded with regard to
route of calcitriol and placebo administration. Blinding was
achieved by the pharmacist who prepared a sealed box with the
specified intravenous and oral dose of calcitriol or placebo for
each patient. Capsules and vials containing placebo were indis-
tinguishable from the calcitriol containing capsules and vials.
Calcitriol was started at an initial dose of 2 g three times a
week. The dose of calcitriol was increased by 0.5 g every two
weeks until the serum calcium was between 10.2 to 10.5 j.sg or
the patients received a maximum calcitriol dose of 4.0 pg with
each treatment. Differences in calcium carbonate intake were
minimized during the initial treatment period so that the relative
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Table 1. Clinical characteristics of hemodialysis patients prior to
treatment with intravenous and "pulse oral" calcitriol
Group
Intravenous Pulse oral
Demographics
Age years 39.2 4,0 41 3.1
Dialysis duration years 4.5 0.9 3.8 0.6
Sex (female/male) 6/4 7/2
Biochemical parametersa
PTH pg/mi 932 158 907 117 (13—65)
Calcium mmol/iiter 2.3 0.05 2.3 0.06 (2.2—2.6)
Phosphorus mmo!/iiter 2.1 0.13 2.4 0.18 (0.9—1.5)
Aluminum .uno!/iiter
1,25 Dihydroxyvitamin D
0.8 0.16
22 4.5
0.9 0.48 (<0.2)
15 1.5 (38—125)
pmoi/!iter
25 Hydroxyvitamin D 45 4.3 43 6 (38—200)
nmo!/liter
Values represent the mean SEM. Numbers in parentheses represent
the normal range. There were no differences in biochemical parameters
between groups as assessed by the Students t-test.
a Toconvert values for calcium to milligrams per deciliter, divide by
0.25; for phosphorus to milligrams per deciliter, divide by 0.323; 1,25
dihydroxyvitamin D to picograms per milliliter and 25 hydroxyvitamin
D to nmol/liter, divide by 2.5; and aluminum to micrograms per liter,
divide by 0.037.
calcemic effects of the different routes of calcitnol administra-
tion could be evaluated. Calcium carbonate was limited to a
maximum dose of 6.25 g (2.5 g elemental calcium) during the
period of calcitriol dose titration (that is, the first 8 weeks).
Aluminum carbonate (Basaljel) was administered only to pa-
tients who could not maintain their serum phosphorus below 2.3
mrnol/liter (7.0 mg/dl) on the maximum allowable dose of
calcium carbonate. Aluminum carbonate administration was
limited to a maximum dose equivalent to 4 g A1(OH)3 per day in
an effort to limit the potential for aluminum toxicity [28].
Upward adjustments of calcitriol doses were not done if the
serum calcium and phosphorus exceeded 2.6 mmol/liter (10.5
mg/dl) and 2.3 mmolAiter (7.0 mg/dl), respectively. Moreover,
calcitriol doses were reduced by 0.5 p.g decrements for mild
hypercalcemia, defined as a serum calcium between 2.6 and 2.9
mmol/liter (10.5 and 11.5 mg/dl). More severe hypercalcemia
[serum calcium >2.9 mmol/liter (11.5 mgldl)] was treated by
stopping all calcitriol and calcium carbonate until the serum
calcium decreased to below 2.6 mmollliter (10.5 mg/dl). The
calcitriol dose was also reduced by successive 0.5 g decre-
ments for uncontrollable hyperphosphatemia, defined as a
persistent elevation of serum phosphorus above 2.3 mmol/liter
(7 mg/dl) in spite of administration of maximum doses of
phosphate binders. If cessation of calcitriol was necessary
because of hypercalcemia or the inability to control serum
phosphorus, calcitriol was restarted at one-half the previous
dose after serum calcium and/or phosphorus levels had declined
to acceptable levels (that is, calcium <10.5 mg/dl and phospho-
rus <7.0 mg/dl).
Of the 19 patients who entered the treatment protocol, 17
completed the planned 36 weeks. One subject in the intrave-
nous calcitriol group left the study after eight weeks to receive
a kidney transplant, whereas the other patient in the oral
calcitriol group dropped out of the study after 24 weeks because
of conversion to peritoneal dialysis.
Diagnostic studies
Biochemicalparameters. During the six-week control period,
serum calcium and phosphorus were assessed weekly. During
the treatment phase, serum calcium and phosphorus were
measured weekly during the first four weeks, every two weeks
during the next eight weeks, and monthly throughout the
remainder of the 36-week treatment period. Additional serum
calcium and phosphorus levels were obtained one week after
adjustment in calcitriol dose or after an episode of hypercalce-
mia. Intact serum PTH concentrations were determined at the
beginning and end of the control period, and monthly thereafter
during the treatment period. Aluminum levels were measured
every three months during treatment phase. 25-Hydroxyvita-
mm D was measured at the outset of the control period and
repeated 24 weeks into the treatment period. Serum 1,25
dihydroxyvitamin D levels were assessed at the outset of the
control period and at 12 and 36 weeks following therapy. In
addition, to define the pharmacokinetics of the two treatment
modalities, serial serum calcitriol determinations were obtained
(15 mm, 30 mm, 1 hr and 48 hr after dosing) at a point during the
treatment period when patients were receiving their maximum
dose of calcitriol.
Serum calcium and phosphorus were measured by an auto-
analyzer (Roche-Cobas Mira S, Montclair, New Jersey, USA).
Serum intact PTH was measured by the Allegro PTH assay kit
(Nichols Institute Diagnostics, San Juan Capistrano, California,
USA) as previously described [29]. 1 ,25-Dihydroxyvitamin D
was measured by a competitive binding assay (Incstar 1,25
dihydroxyvitamin D 3HRRA kit, Stillwater, Minnesota, USA).
25-Hydroxyvitamin D was analyzed by a radioimmunoassay
(Nichols Institute Diagnostics). Serum aluminum was measure
by as previously described using a flameless atomic absorption
spectrophotometer (Perkins-Elmer Corp., Norwalk, Connecti-
cut, USA) [30]. Ionized calcium was measured using an ion
specific flow through electrode (Radiometer ICA, Copenhagen,
Denmark). In addition, the total phosphate binding capacity
was calculated from the amount of elemental phosphorus that is
bound by calcium carbonate (116 mg per g CaCO3) or aluminum
hydroxide [161 mg per g of Al(OH)3] as empirically determined
from metabolic balance studies [31].
Calcemic suppression of PTH secretion. Prior to initiation of
calcitriol treatment and again at the end of 36 weeks of therapy,
a dynamic calcium-mediated PTH suppression test was per-
formed using modifications of methods reported by Delmez et al
[10]. This test has been successfully employed to evaluate
parathyroid gland sensitivity to calcium before and after cal-
citriol therapy in patients with ESRD. The protocol consisted of
serial measurement of serum intact PTH and ionized calcium
during hemodialysis employing a dialysate containing supra-
physiologic calcium concentrations (3.5mEq/literor 1.75 mmol/
liter). Blood was sampled for serum ionized calcium and intact
PTH measurements prior to starting dialysis (time 0) and at 2,5,
10, 20, 30, 60, 90, 120, 150, 180 minutes during high calcium
dialysis. From data obtained, regression analysis between se-
rum ionized calcium and intact PTH was constructed for each
patient to define the relationship between increments in serum
ionized calcium and changes in PTH. We defined: the minimum
PTH as the lowest PTH value obtained during the treatment
with high calcium dialysate; the calcium EC50 as the ionized
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calcium concentration that caused a 50% decline in PTH levels
during each dialysis treatment with 3.5 mEq/liter calcium; and
the slope as the change in PTH per 0.01 mmollliter change in
ionized calcium over the linear region of the regression between
calcium and PTH [101.
Parathyroid gland imaging. At the end of the control period
and after 36 weeks of therapy, patients in both treatment groups
were scheduled for imaging studies to assess parathyroid gland
size. Of the 19 subjects, pre- and post-imaging studies were
successfully obtained in 14. The other five participants either
refused imaging studies (3 patients) or had dropped out of the
study prior to the scheduled imaging procedure (2 patients).
Parathyroid glands were assessed by high resolution ultrasound
in 12 patients before and after treatment. In the remaining two
subjects magnetic resonance imaging was used for the initial
assessment of gland size and ultrasound was used for the
post-treatment assessment of gland size. For both imaging
techniques, visualized glands were measured in the anterio-
posterior, transverse, and longitudinal dimensions to calculate
parathyroid volumes. In addition, changes in gland size were
determined by paired analysis. Ultrasound examinations were
performed with an Acuson 128 or 128-XP machine using a 7.5
MHz linear phased array transducer [321. The axial resolution
and lateral resolution are 0.5 and 1 mm, respectively, for
ultrasound. This technique can resolve between a I and 2 mm
change in size of enlarged parathyroid glands. Normal parathy-
roid glands, which measure approximately 5 x 3 x 1 mm, are
not reproducibly visualized by high resolution ultrasound. The
accuracy, sensitivity and specificity of high resolution ultra-
sound for detecting enlarged parathyroid glands are 91%, 73%
and 91% [33, 341. Magnetic resonance (MR) examinations of
parathyroid glands were performed with a 1.5 Tesia GE Signa
system as previously described [35]. For MR, imaging was
performed in the axial plane utilizing both short TRITE (Ti
weighted images), long TRlshort TE, and long TRITE spin echo
(SE) pulse sequences (proton density and T2 weighted images).
The overall resolution of MR is 5 mm. The accuracy, sensitivity
and specificity of MR are 90%, 78% and 95% for detecting
enlarged parathyroid glands [32, 35].
Statistical analysis
Time-dependent changes and group differences with regard to
serum intact P1'H, calcium and phosphorus during the 36-week
treatment period were analyzed using estimated generalized
least squares first order autoregressive (AR1) models for time
series measures with missing values [36]. Each model evaluated
the effect of treatment (intravenous vs. oral therapy), time
(weeks 0 to 36), time2 and the differential effect of treatment
over time on the biochemistry of interest. Consideration of
sample size and the many possible combinations of two-way
tests of time differences for each biochemistry led us to limit the
overall number of significance testing between various times.
The gland volume, gland number, minimum PTH, calcium
EC50, and slope of the dynamic calcium/PTH regression were
evaluated at weeks 0 and 36 only. Generalized least squares
AR1 models were again used to test the four pairwise differ-
ences of treatment effects at each of the two time points and/or
change over time for each of the two treatment groups. Multi-
variable analysis was performed to determine the factors that
correlated with the observed changes in intact PTH. For this
analysis, a subset of eight variables (time, serum calcium and
phosphorus, calcitnol dose, gland volume, minimum PTH,
calcium EC50 and slope) were specified to investigate the effect
of these factors on the time-dependent alterations in serum PTH
concentrations. Repeated measures with an AR1 variance esti-
mator was used and the variable selection process was back-
wards elimination. To assess the complication rates between
the two treatment groups we employed the Fisher's exact test
to compare the episodes of hypercalcemia and hyperphos-
phatemia and used the Student's t-test to compare the fre-
quency of hypercalcemia and hyperphosphatemia between the
two treatment groups.
Results
Patient characteristics
Both groups were similar with regard to age, duration of
hemodialysis, and all biochemical parameters (Table 1). In
particular, serum intact PTH values were identical in the
intravenous and pulse oral groups at the outset of the control
period. The average PTH value was approximately 14 times the
normal upper limit (range 349 to 1494 pg/ml), which represents
severe hyperparathyroidism [29]. Patients chosen to receive
pulse oral calcitriol had a greater percentage of female patients
compared to the intravenous group. All patients had diminished
serum calcitriol levels.
Control period
During the control period we observed no differences in
dietary calcium or phosphorus intakes between the two groups
(Table 2). The average estimated phosphorus intake was below
the prescribed dose of 900 mg in both groups. Dietary calcium
intake also was lower than the recommended 500 mg daily
elemental calcium intake. To achieve adequate calcium intake
and control of serum phosphorus, we administered an average
of 5.4 grams of calcium carbonate to both intravenous and pulse
oral groups during the six-week control period prior to starting
calcitriol therapy (Table 2). The combination of dietary calcium
intake and calcium carbonate administration resulted in a total
daily elemental calcium intake that averaged 2.4 grams in both
groups. Aluminum-containing antacids (less than 1 g) were
required to control serum phosphorus in several patients in both
groups during the control period (Table 2).
The intact PTH remained stable in both groups during the
control period (week —6 to 0; Fig. iA). In contrast, the serum
calcium increased over the six-week control period in the group
randomized to receive intravenous calcitriol and decreased
slightly in those patients who were to be treated with oral
calcitriol (Fig. IB). By the beginning of calcitriol administration
(time 0) the serum calcium levels were greater in the intrave-
nous compared to the oral calcitriol group (vide infra; Fig. 1B).
Serum phosphorus concentration averaged below 6.5 mg/dl in
both groups by the end of the control period (Fig. iC). How-
ever, in spite of similar dietary phosphate intake and binder
administration, patients randomized to receive pulse oral cal-
citriol had a higher serum phosphorus level than the intrave-
nous group by the end of the control period prior to calcitriol
treatment (vide infra; Fig. 1C).
1714 Quarles et a!: Calcitriol therapy in hyperparathyroidism
Table 2. Mean alterations in dietary calcium and phosphorus intake and dose of I ,25-dihydroxyvitamin D, calcium carbonate and aluminum
hydroxide during the control and treatment periods with intravenous or "pulse oral" calcitriol
Time (weeks):
Control
period
—6 to 0
Treatment period
0 to 4 4 to 8 8 to 12 12 to 16
Dietary intake
Calcium mg/day
Intravenous 287 45 359 89 287 37 230 38 290 41
Oral 285 33 306 47 302 68 299 55 327 34
Phosphorus mg/day
Intravenous 684 77 720 133 799 77 592 110 635 112
Oral 690 66 743 78 644 63 632 84 843 71
Therapy
CaCO3 mg/day
Intravenous 5413 513 5688 343 5375 418 5780 470 6458 333
Oral 5360 528 5590 448 6180 163 6390 140 6320 493
A1(OH)3 mg/day
Intravenous 948 374 1275 403 1900 472 2250 489 2306 507
Oral 700 341 1806 518 2306 484 2875 522 3000 441
I ,25-Dihydroxyvitamin D pg/dose
Intravenous 0 2.3 0.02 2.5 0.32 2.3 0.56 2.2 0.52
Oral 0 2.2 0.05 2.2 0.28 2.3 0.43 2.4 0.51
Phosphate bindingt' mg P042 bound/day
Intravenous 404 61 469 65 555 60 630 78 671 77
Oral 361 52 550 76 656 78 759 87 790 68
Elemental calcium intake mg/day
Intravenous 2452 228 2634 89 2436 179 2543 199 2862 118
Oral 2430 233 2510 189 2771 103 2855 65 2791 224
Table 2. Continued
Time (weeks):
Treatment period
16 to 20 20 to 24 24 to 28 28 to 32 32 to 36
Dietary intake
Calcium mg/day
Intravenous 271 37 241 48 190 44 284 92 252 56
Oral 315 60 307 50 375 64 407 81 298 40
Phosphorus mg/day
Intravenous 563 77 631 123 583 99 600 97 552 103
Oral 696 96 650 72 832 95 720 72 721 123
Therapy
CaCO3 mg/day
Intravenous 6320 515 5868 998 6770 988 6493 1040 6875 955
Oral 7048 633 6980 465 6953 663 6953 610 7773 750
Al(OH)3 mg/day
Intravenous 2528 483 2028 459 1806 530 2167 447 2083 437
Oral 2889 425 2972 494 2469 666 2438 570 2688 517
1 ,25-Dihydroxyvitamin D pg/dose
Intravenous 2.1 0.49 1.6 0.50 1.7 0.50 1,4 0.46 1.2 0.44
Oral 1.9 0.54 1.5 0.51 1.5 0.43 1.5 0.49 1.3 0.55
Phosphate binding' mg P04' bound/day
Intravenous 700 85 598 96 605 117 650 101 654 91
Oral 792 71 802 82 720 100 715 93 784 95
Elemental calcium intake mg/day
Intravenous 2794 247 2480 423 2685 571 3132 617 2874 651
Oral 2940 233 3076 200 3156 290 3085 318 3073 356
Values represent mean SEM.
a ,25-Dihydroxyvitamin D was administered at the end of dialysis thrice weeklyb Represents the estimated total binding capacity in mg of dietary phosphate bound obtained by calcium carbonate and aluminum hydroxide
administration
There were no significant differences in parathyroid gland
number (P = 0.317) and volume (P = 0.785) between intrave-
nous and oral groups prior to treatment (Table 3). Moreover,
the slope, calcium EC50 and minimal PTH derived from calcium
suppression studies were the same in both groups prior to
initiating treatment with calcitriol (Table 3).
Treatment period
Dietary intake and therapeutic interventions. During the 36
week treatment with calcitriol the average dietary phosphorus
and calcium intake remained similar in both treatment groups
(Table 2). The amount of administered calcium carbonate also
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Fig. 1. Differences in the serum 1,25-dihydroxyvitamin D levels follow-
ing administration of intravenous (0) and pulse oral (•) calcitriol.
Values were obtained from 7 subjects treated with intravenous and 6
subjects treated with oral calcitriol at their maximum calcitriol dose,
which respectively averaged 3.6 and 3.3 sg/treatment. Serum 1,25-
dihydroxyvitamin D levels were 480 pmol/liter (192 pg/mI) and 48
pmol/liter (19 pg/mI) at 15 minutes following intravenous calcitriol
administration and pulse oral administration, respectively. By 60 min-
utes, the serum I ,25-dihydroxyvitamin D levels had decreased to 389
pmollliter (155 pg/mI) in the intravenous group and had risen to 128
pmol/liter (51 pg/mI) in the oral group. The peak serum calcitriol level
following oral administration, which typically occurs after 4 to 6 hours
[18], was not measured in these patients. In both groups serum
1 ,25-hydroxyvitamin D levels returned to pre-treatment values by 48
hours after calcitriol administration.
remained stable over the first eight weeks (during the initial
period of calcitriol dose titration) but thereafter increased in a
progressive fashion in both groups. By the end of the 36-week
treatment period, the average calcium carbonate dose had
increased by 27 and 45% in the intravenous and pulse oral group
compared to doses administered during the control period. An
increase in the average dose of aluminum hydroxide also was
required to maintain control of serum phosphorus following
treatment with calcitnol. The aluminum hydroxide dose in-
creased by approximately 120 and 284% in the intravenous and
oral group by end of the 36-week treatment period (Table 2).
The total phosphate binding capacity, which represents the
combined estimated dietary phosphate binding derived from
orally administered aluminum hydroxide and calcium carbon-
ate, increased by 61% in the intravenous group and by 117% in
the pulse oral group during the course of treatment with
calcitriol (Table 2).
The average calcitriol dose was similar in both the intrave-
nous and oral groups throughout the 36-week treatment period.
In spite of efforts to administer 4 tg of calcitriol per dose to
Table 3. Estimate parathyroid gland size and dynamic indices of
calcium-mediated PTH suppression before and 36 weeks after
treatment with intravenous or "pulse oral" calcitriol
Time weeks
0 36
Parathyroid gland sizea
Gland number #/patient
Intravenous 2.3 0.5 3.1 0.4
Oral 3.0 0.7 3.0 0.8
Gland volume cm3/patient
Intravenous 1.9 0.6 3.3 0.8
Oral 2.1 0.7 2.3 0.8
Calcium-mediated PTH
suppressionb
Minimum PTH pg/mlC
Intravenous 444 101 (48%) 379 112 (48%)
Oral 249 48 (67%) 319 80 (57%)
Calcium EC50 mmol/liter
Intravenous 1.21 0.04 1.24 0.03
Oral 1.24 0.03 1.22 0.03
Slope iPTH/O.O1 mM Ca
Intravenous 66 25 43 21
Oral 78±23 78±23
Values represent mean SEM. Values in parentheses are percent
decrements from baseline.
No significant differences in any parameter were observed within
groups or between groups before and after therapy.
a Consists of 8 patients treated with intravenous and 6 patients
treated with pulse oral calcitriol
b Consists of 8 patients treated with intravenous and 8 patients
treated with pulse oral calcitriol
C Represents the lowest (maximally suppressed) PTH value induced
by high calcium dialysate
each patient, the respective maximum dose of calcitriol aver-
aged only 2.5 and 2.4 zg per dose in the intravenous and pulse
oral groups. Indeed, only two patients in each treatment group
attained the 4 g target calcitriol dose. Dosage reductions were
in response to development of hypercalcemia and/or refractory
hyperphosphatemia (vide infra). By the end of the study, the
average calcitriol dose had decreased to approximately one-half
of the highest attainable dose (Table 2).
We measured the serum 1,25 dihydroxyvitamin D levels
following the administration of a maximum calcitriol dose in a
subset of subjects from each treatment group: seven from the
intravenous and six from the pulse oral group (Fig. 1). Similar to
previous reports [10], serum calcitriol levels peaked at a level of
489 pmol/liter (192 pg/ml) by 15 minutes and remained at
pharmacologic levels of 389 pmol/liter (155 pg/ml) at 60 minutes
following the intravenous route of administration. In contrast,
the rise in serum 1,25 dihydroxyvitamin D after oral adminis-
tration was more gradual. Calcitriol levels were 48 pmollliter (19
pg/mI) after 15 minutes and increased to near the upper normal
limit (128 pmol/liter or 51 pg/ml) by 60 minutes after oral
calcitnol administration. The serum calcitriol levels had re-
turned to baseline values by 48 hours, prior to the next calcitriol
dose. We measured such trough levels of calcitriol in all
patients at different time points though out the 36-week treat-
ment period. The trough serum 1,25 dihydroxyvitamin D levels
(pg/mi) measured in the intravenous and oral groups at 12 weeks
were 42.5 + 10 versus 35 + 7.5 pmol/liter (17 4 vs. 14 3) and
at 36 weeks were 30 + 7.7 versus 48 + 7.6 pmollliter (12 3 vs.
19 3 pg/mi).
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Alterations in serum PTH concentrations. We found no
difference with regards to serum PTH reductions between the
intravenous and oral groups (P = 0.298; Fig. 2A). Indeed, the
response of PTH over time was identical irrespective of treat-
ment (such as, no significant interaction existed for treatment
with time; P = 0.185). We did observe an overall reduction in
serum PTH levels over time (P = 0.016; Fig. 2A). The time-
dependent suppression of PTH was curvilinear with the major-
ity of the suppression occurring in the initial 12 to 16 weeks of
therapy (Fig. 2). The maximum serum PTH suppression was
56% in the intravenous group and 29% in the pulse oral group
(overall reduction in both groups averaged 43%). The ability to
maintain this degree of PTH suppression was not sustained,
however, since by the end of the treatment period the percent
reduction in PTH averaged only 27% and 17% in the intrave-
nous and oral groups, respectively (Fig. 2A).
Within each group, we observed heterogeneity in the degree
of PTH suppression among individual patients (Fig. 3A, B). In
the intravenous group, five patients showed progressive reduc-
tions of serum intact P'I'H levels (Fig. 3A), whereas the remain-
ing five patients showed no net reduction in PTH over the
course of treatment (Fig. 3B). Similar variable responses were
observed in the pulse oral group [4 responders (Fig. 3A);
5 non-responders (Fig. SB)]. The basis of non-responsiveness
(vide infra) was not related to the dose of calcitriol (which
averaged 1.0 0.4 and 1.4 0.6 p.g in responders and
non-responders at 36 weeks, respectively; P = 0.60). Indeed,
four patients (2 in each group) displayed no suppression of PTH
in spite of achieving the target calcitriol dose of 4 g thrice
weekly.
Alterations in other serum biochemical parameters. Cal-
citriol administration was associated with an overall significant
increase in calcium over time in both groups (P = 0.007; Fig.
2B). The increment in calcium was apparent by week 4;
thereafter the serum calcium levels did not increase further in
spite of a gradual increment in calcium supplementation (Table
2). Patients treated with intravenous calcitriol displayed a
greater serum calcium concentration compared to individuals
treated with pulse oral therapy (P = 0.026) throughout the 36-
week treatment period. This difference between groups, how-
ever, was not merely related to treatment since calcium levels
were dissimilar before beginning calcitriol administration (Fig.
2B). We observed no interaction between treatment and time
with regard to serum calcium levels (P = 0.722).
We observed no significant difference in serum phosphorus
concentrations over time (P = 0.2149; Fig. 2C). Maintenance of
serum phosphorus was accomplished, however, at the expense
of progressive increments in phosphate binder administration
(Table 2). Phosphate binding capacity was approximately two-
fold greater at the end of the study compared to that required to
control the serum phosphorus level during the control period
(Table 2). In addition, the difference between the serum phos-
phorus levels between the two groups that was observed at the
end of the control period was maintained during the entire 36-
week calcitriol treatment period (P = 0.0028; Fig. 2C). We
observed no interaction between treatment and time with
regard to serum phosphorus concentrations (P = 0.801).
Though aluminum containing phosphate binders were given,
serum aluminum levels did not change over time or in response
to the different treatment regimens. Prior to treatment, serum
aluminum concentrations averaged 29 9.0 and 24 6.8
pg/liter in patients randomized to receive intravenous and oral
therapy, respectively. Following treatment, serum aluminum
levels (Lg/liter) were 24 5 and 30 6 at 12 weeks and 35 9
and 25 7 at 36 weeks in subjects treated with intravenous and
oral calcitriol, respectively.
Indices of gland size and calcium-mediated suppression of
PTH. We detected enlarged parathyroid glands in all but three
subjects prior to therapy. Individual gland size in our ESRD
patients ranged from 4 mm to 2.4 cm, similar to that reported by
others [34]. We observed no treatment effect to reduce either
the average gland volume or number after 36 weeks of calcitriol
administration. In addition, there were no differences between
the intravenous and oral treatment groups with regard to gland
number or volume (P = 0.541 and 0.842) at the end of the 36-
week treatment period (Table 3). Paired analysis of individual
parathyroid glands visualized by ultrasound before and after
treatment consistently failed to show a reduction in gland size
following calcitriol therapy.
Treatment with either intravenous or pulse oral calcitriol also
did not alter calcium mediated suppression of PTH (Table 3).
Neither the minimum PTH, the slope of PTH/calcium response
curves, nor the calcium EC50 were altered by either intravenous
or "pulse" oral calcitriol therapy.
Multi-variable analysis offactors affecting PTH suppression.
We found that the significant predictors of the time-dependent
changes in serum PTH included serum calcium and phosphorus
concentrations as well as indices of calcium-mediated VFH
suppression. Calcium was inversely related to changes in PTH
(P = 0.0001)—as calcium increases, PTH decreases—whereas
phosphorus was directly related to changes in PTH (P =
0.0001)—as phosphorus increases, PTH increases. Minimum
PTH, which reflects the lowest PTH value obtained during
calcium loading was positively correlated with the changes in
PTH (P = 0.0001), that is, the inability to suppress PTH was
related to the refractoriness to calcitriol therapy. Finally, cal-
cium EC50, which defines the ionized calcium associated with a
50% reduction in PTH during high calcium dialysis, was posi-
tively correlated to changes in PTH (P = 0.01)-thegreater the
calcium concentration needed to suppress PTH, the greater the
refractoriness to therapy. Other variables used in the model
which included 1 ,25-dihydroxyvitamin D dose, gland volume
and slope of the PTH suppression derived from high calcium
dialysate did not account for the observed changes in PTH
following calcitriol treatment.
Complications of therapy. There were no significant differ-
ences in the number of episodes of hyperphosphatemia or
hypercalcemia between treatment groups, though the overall
incidence and prevalence of these complications were impres-
sive (Table 4). In this regard, 80% of subjects treated with
intravenous calcitriol and 56% of patients treated with oral
calcitriol developed at least one episode of hypercalcemia. The
overall frequency of hypercalcemia averaged 7.5 1.8 episodes
per 100 patient weeks of therapy in the intravenous calcitriol
group and 5.1 2.2 episodes per 100 patient weeks in the oral
calcitriol group (P = 0.475). With regard to control of serum
phosphorus, 70% of subjects treated with intravenous calcitriol
and 100% of patients treated with oral calcitriol developed at
least one episode of hyperphosphatemia during the treatment
period. The overall frequency of hyperphosphatemia over the
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Fig. 2. Changes in serum biochemical parameters following
treatment with intravenous and pulse oral calcitriol for 36 weeks. (A)
Effects of calcitriol therapy on serum intact PTH, (B) total serum
calcium, and (C) serum phosphorus concentrations. Week —6
through 0 represents the control period during which calcitriol was
not administered. Calcitriol therapy was started at time zero as
indicated by the arrow. The intravenous calcitriolloral placebo group
is represented by the solid line (—), whereas the pulse oral
calcitriollintravenous placebo group is represented by the interrupted
line ( ). The suppression of PTH over time was identical
irrespective of treatment group (time effect, P = 0.016); group effect,P = 0.298; interaction between time and group, P = 0.185). Serum
calcium significantly increased over time (P = 0.007). There was also
a significant difference in calcium between groups that was apparent
prior to calcitriol treatment (P = 0.0260). There was no difference in
serum phosphorus over time (P = 0.215), but serum phosphorus was
significantly greater in the oral group before and after initiation of
calcitriol therapy (P = 0.0028). There was no interaction between
group and time with regard to either calcium (P = 0.772) or
phosphorus (P = 0.801). Values represent the mean SEM.
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Fig. 3. Heterogeneity in suppression of serum intact PTH following
treatment with intravenous and pulse oral cakitriolfor 36 weeks, Week
—6 through 0 represents the control period during which calcitriol was
not administered. Calcitriol therapy was started at time zero. Individual
patients in the intravenous calcitriol/oral placebo group are represented
by a solid box and line (—U—); each subject in the pulse oral
calcitriol/intravenous placebo group is represented by an open box and
an interrupted line (----D ). (A) Subjects displaying a progressive
reduction in PTH following calcitriol treatment. (B) Subjects showing
no net change in PTH following calcitriol treatment. The variable
response was related to the increments in calcium (positive effect),
hyperphosphatemia (negative effect), but not to the dose of calcitriol
(see text), Differences related to parathyroid calcium sensitivity (calci-
um EC50 and minimum PTH value) as defined by calcium suppression
studies also contributed to the variable suppression of PTH.
Intravenous Pulse oral
Episodes/ Episodes!
Ratio 100 patient Ratio 100 patient
(%) weeks' (%)0 week&'
Hypercalcemiac
Hyperphosphatemiad
8/10 (80)
7/10 (70)
8 2
21 10
5/9 (56)
9/9 (100)
5 2
21 4
a Values expressed as a ratio represent the number of subjects
developing at least one episode of hypercalcemia or hyperphosphatemia
during the 36-week observation period. There were no differences
between groups as assessed by Fisher's exact test.
b The total number of complications in each group during the
treatment period is expressed as episodes per 100 patient weeks. There
were no differences between groups as assessed by Student's t-test.
C Defined as a total serum calcium exceeding 10.5 mg/dl
d Defined as serum phosphate exceeding 7.0 mg/dl
36-week treatment period averaged 21 10 episodes per 100
patient weeks in the intravenous and 21 4 episodes per 100
patient weeks in the oral calcitriol group (P = 0.890).
Discussion
The results from this controlled randomized clinical trial
indicate that long-term intermittent oral and intravenous cal-
citriol therapy are equivalent in treating severe secondary
hyperparathyroidism in chronic hemodialysis patients. Though
small differences were observed between the groups during the
initial eight weeks of therapy, the time-dependent reductions in
serum PTH levels over the entire 36-week observation period
were not statistically different between intravenous or oral
calcitriol (Fig. 2A). Indeed, the percent reduction in PTH was
identical in the two groups by the end of the study period (Fig.
2A). The equivalent reduction in PTH was achieved in the pulse
oral group without the rapid supra-physiologic serum calcitriol
concentrations attained after intravenous calcitriol administra-
tion (Fig. 1). In addition, failure to observe greater PTH
suppression following intravenous therapy occurred in spite of
a higher serum calcium and lower serum phosphorus levels
(conditions that should augment PTH suppression) in intrave-
nous compared to the pulse oral group (Fig. 2B, C).
Our study lacks sufficient power to detect smaller differences
in PTH suppression between oral and intravenous groups.
Indeed, our sample size was selected to detect a 50% difference
between intravenous and pulse oral therapy with power of 80%
A
Table 4. Complication of treatment with intravenous and "pulse
oral" calcitriol
—8 —4 0 4 8 12 16 20 24 28 32 36 40
Time weeks
B
2000
1900
1800
1700
1600
1500
1400
1300
1200
1100
10000
• 900
800
700
600
500
400
300
200
100
0
3000 -
2800
2600
2400
2200
2000 -
1800-
1600-
°- 1400-
1200-
1000-
800 -
600 -
400 -
200 -
0— 11111111111111 I I III
—8 —4 0 4 8 12 16 20 24 28 32 36 40
Time weeks
Quarles et a!: Calcitriol therapy in hyperparathyroidism 1719
or better. In any event, the minimal difference between the
study groups early in the course of therapy, even if proven to be
statistically significant by enrolling larger numbers of patients,
is likely to be clinically inconsequential and is not sustainable.
It is also important to note that our treatment paradigm was
designed to manipulate oral and intravenous calcitriol dosage in
the setting of fixed calcium supplementation. The ability to
achieve long-term reductions in serum FFH levels may have
been limited by the reduction in calcitriol dose that was
necessitated by the intolerance to our therapeutic regimen
(vide infra). Whether other treatment strategies using different
combinations of calcium carbonate and calcitriol or alternate
methods for controlling phosphorus will result in long-term
suppression of PTH in severe hyperparathyroidism without
hypercalcemia and hyperphosphatemia remains to be evalu-
ated.
In any event, our results indicate that the treatment of severe
hyperparathyroidism remains diflicult in subjects with end-
stage renal failure regardless of route of calcitriol administra-
tion. The basis for this refractoriness is unclear but may
represent a combination of increased functioning gland mass
(diffuse hyperplasia and hypertrophy) (Table 3), abnormalities
related to vitamin D receptor deficiency [36], limited tolerance
to high calcitriol dosage (Table 2), altered calcium sensitivity in
individual parathyroid cells (Table 3) [10], and/or monoclonal
growth of autonomous parathyroid secreting cells in some
patients [37, 38]. Overall, we found that the dose of calcitriol
was limited by side effects (Table 4) and that the average PTH
levels rebounded as the calcitriol dose was reduced in both
groups (Fig. 2A). In individual patients, we observed marked
heterogeneity in the response to intensive calcitriol therapy in
both treatment groups that was not merely related to calcitriol
dose. Indeed, 45% of patients in our study displayed an
adequate therapeutic response as assessed by progressive re-
ductions in serum PTH levels at low calcitriol doses; 21%
displayed no reduction in serum PTH, even after achieving and
maintaining calcitriol doses of 4 g per treatment, and the
remaining 24% displayed variable PTH suppression (Table 4).
In addition, we observed, similar to recent findings by Fischer
and Harris [39] no decrement in estimated gland volume or
number in either the pulse oral or intravenous calcitriol treated
group (Table 3). This failure to induce apoptosis of hyperplastic
parathyroid tissue is consistent with animal studies of uremic
hyperparathyroidism, where calcitriol administration prevents
the development of hyperplasia but does not induce regression
of pre-existing parathyroid gland enlargement [9]. In multivari-
able analysis, neither the route, calcitriol dose or parathyroid
gland enlargement accounted for the lack of effectiveness of
calcitriol therapy in our patients. Instead, we found that dys-
regulated parathyroid hormone secretion, as assessed by resis-
tance to calcium-mediated suppression of PTH, accounted, in
part, for the variable therapeutic responses. This observation is
consistent with the observed insensitivity of parathyroid secre-
tion to calcium found in uremia [I] and may be related to the
decreased 1 ,25-dihydroxyvitamin D receptor density associated
with severe parathyroid hyperplasia in some patients with
ESRD [37]. The degree of hyperphosphatemia also contributed
to the resistance to calcitriol treatment in our study.
Regardless, our findings do not substantiate earlier uncon-
trolled studies purporting advantages of intravenous calcitriol
over oral calcitnol. Conclusions from these studies [17—20] are
limited by their failure to directly compare different regimen, by
their lack of efforts to randomize subjects thereby resulting in
hyperparathyroidism of different severity in the various treat-
ment groups. Subjects responsive to intravenous calcitriol
generally have milder degrees of hyperparathyroidism than
refractory subjects treated with oral calcitriol, and/or by un-
equal manipulation of covariables, such as calcium administra-
tion and dialysate calcium concentrations that may, indepen-
dent of calcitriol, influence the therapeutic response and rates
of complications in the different treatment groups. The weight
of existing evidence supports the conclusion that in responsive
patients the route of calcitriol is not as important as providing
sufficient calcitriol to achieve physiologic serum calcitriol con-
centrations [15]. Moreover, we found that neither intravenous
nor oral calcitriol is effective in controlling a large subset of
patients with refractory hyperparathyroidism. Our finding dif-
fers from studies showing a greater than 50% reduction in PTH
following calcitriol therapy [15, 18, 40, 41], but is similar to
more modest response observed in other studies that include
patients with severe hyperparathyroidism [17]. Such differences
also may be related to individual heterogeneity in responsive-
ness and the intensity and duration of the treatment regimens as
well as to differences in the severity of hyperparathyroidism.
Of note, in contrast to previous studies by Delmez et al [10],
the functional abnormalities of PTH secretion (as defined hy-
percalcemic PTH suppression during dialysis) were not affected
by calcitriol therapy (Table 3). Using a similar protocol to
assess parathyroid gland function, we failed to detect any
alterations in the slope of the PTH/calcium response curve or
the calcium EC50 for PTH suppression after 36 weeks of
treatment with calcitriol. Our studies are consistent with previ-
ous studies that also failed to show an effect of intravenous
calcitriol to alter the calcium set point [42]. These discrepancies
may be related to the duration of therapy and/or the dose of
calcitriol. Indeed, calcitriol altered the calcium set point in
dialysis patients after therapy with 3 g with each dialysis for
two weeks [10], whereas in our studies we failed to normalize
dynamic indices of PTH secretion in subjects at a time when
they were treated with a dose of calcitriol that averaged 1.5 g.
In addition, a more complete analysis of the sigmoidal relation-
ship between calcium and PTH derived from hypocalcemic
stimulation and hypercalcemic suppression may be necessary
to detect calcitriol induced alterations in parathyroid gland
function [41].
Finally, one of the basic tenants of intravenous calcitriol
therapy, derived from uncontrolled trials, is that the intrave-
nous route results in less hypercalcemia than the oral route of
administration; our current investigation does not support this
widely held view. Our trial, which compares similar doses of
pulse oral and intravenous calcitriol in the setting of nearly
identical calcium intake and dialysate calcium, shows that both
routes of chronic calcitriol administration are associated with
the development of hypercalcemia (Table 4). In addition, both
treatment modalities were associated with a greater difficulty in
controlling hyperphosphatemia, possibly related to enhanced
gastrointestinal absorption of phosphorus and/or its release
from osseous stores or decreased bone buffering. The problems
with controlling serum phosphorus during the treatment period
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are evident both from the increased episodes of hyperphos-
phatemia (Table 4) and the need to increase the dose of dietary
phosphate binders after the initiation of calcitriol therapy (Table
2). Because of hypercalcemia and hyperphosphatemia, the
pharmacologic doses of calcitriol reported to be effective in
short-term clinical trials could not be tolerated by either the oral
or intravenous route in our study. As noted, the propensity to
develop hypercalcemia and hyperphosphatemia limited the
average calcitriol doses to approximately 1.5 g per treatment,
a value similar to that reported by the Italian group for the study
of intravenous calcitriol [20].
Our study represents the first controlled randomized compar-
ison of pulse oral and intravenous calcitriol in the treatment of
uremic secondary hyperparathyroidism. We found no advan-
tage of one over the other treatment modality with regard to
efficacy or side effects. Moreover, we found that long-term
intensive intravenous and oral calcitriol therapy failed to cor-
rect abnormalities in parathyroid gland size and function.
Rather, the response to treatment of hyperparathyroidism in
our subjects was heterogeneous, consisting of patients who
were either responsive or refractory to calcitriol. Further stud-
ies are needed to define the mechanism(s) of refractory hyper-
parathyroidism that may include monoclonal expansion of
autonomous cells [37], abnormalities of vitamin D receptor
up-regulation in response to calcitriol therapy [36], and/or
abnormalities of calcium receptor coupling to intracellular
signals in parathyroid cells [43]. Moreover, our study focused
only on alterations in parathyroid gland function. Effects of
intensive calcjtrjol on bone metabolism is another factor that
needs additional study. In addition, we need to determine if
early intervention with calcitriol will prevent glandular hyper-
plasia and correct abnormalities of PTH secretion [44] as well as
examine the long-term sequelae of patients who display partial
reductions in serum PTH levels after therapy. In view of the
inability of calcitriol to effectively treat hyperparathyroidism in
many patients, newer vitamin D analogues [45] and/or calcimi-
metic agents [46], which in experimental models can reduce
PTH secretion without increasing serum calcium , may offer
exciting potential new therapies for management of refractory
hyperparathyroidism in ESRD.
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